Moat
82.0/10
Large-scale pharmaceutical distribution has high operational, regulatory, data, contracting, and working-capital barriers; Cencora's fiscal 2025 scale and distribution-network investments support a strong moat.
CORQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 201-225; refreshed with public company, market-data, open-source, and standards sources available on 2026-06-02.
Cencora
Cencora distributes pharmaceuticals and provides services supporting drug access, commercialization, and specialty care.
Metadata
Where this company sits
- Ticker
- COR
- Rank snapshot
- ≈ 201
- Sector
- Health Care
- Industry
- Health Care Distributors
- Region
- United States
- Index
- S&P 500 · Top 225 by market cap
Metrics
Scoring view
Every metric is paired with a short rationale. The numbers are deliberate, not divine.
Decentralizability
36.0/10
Inventory software, traceability events, and some logistics coordination can decentralize, but drug custody, manufacturer contracts, regulated wholesaling, and specialty handling constrain full replacement.
Profitability
48.0/10
Cencora is profitable and large, but pharmaceutical distribution remains a very low-margin business; fiscal 2025 adjusted operating income of about $4.2 billion on about $321.3 billion of revenue implies limited operating-margin headroom.
Price / Earnings
20.5x
StockAnalysis reported a trailing P/E ratio of 20.46 for COR at the May 27, 2026 close.
Market cap
$52.0B
StockAnalysis reported Cencora market capitalization of about $51.95 billion at the May 27, 2026 close.
Freed-up capital potential
$0.0
Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.
Narrative
Why the company matters
A short editorial overview plus the current thesis on moat strength and decentralization pressure.
Business mix
Cencora is a major pharmaceutical sourcing and distribution company serving healthcare providers, pharmacies, health systems, and pharmaceutical and biotech manufacturers in the United States and internationally.
Its scale is concentrated in drug distribution, specialty services, and logistics infrastructure, with fiscal 2025 revenue of about $321.3 billion and adjusted operating income of about $4.2 billion.
Specialty services
Cencora's World Courier and related logistics businesses support clinical trial, specialty pharmaceutical, and cell-and-gene-therapy supply chains where temperature control, chain of custody, and regulatory execution matter.
The company has also highlighted investments to strengthen U.S. distribution-network capacity and resilience, reinforcing the centrality of physical infrastructure to its moat.
Moat reading
Cencora's moat comes from scale, regulated distribution relationships, purchasing and sourcing networks, specialty logistics capabilities, and operational trust built around moving high-value medicines through compliant channels.
The business is structurally low-margin but hard to displace quickly because manufacturers, pharmacies, hospitals, and specialty-care sites depend on reliable fulfillment, cold-chain discipline, inventory availability, and data exchange across regulated workflows.
Decentralization reading
Cencora is not primarily a software monopoly, so disruption is less about replacing an app and more about unbundling coordination, inventory visibility, traceability, and local logistics execution from a few national wholesalers.
Open-source health commodity systems, interoperable traceability standards, cooperative buying groups, and federated cold-chain networks could pressure parts of the model, but regulated pharmaceutical custody, manufacturer contracts, payer relationships, and liability constraints make full decentralization difficult.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 2 structured disruption concepts across the current product set.
2 disruption concepts tracked0 documented exceptions
Pharmaceutical distribution
Health care supply chain
1 conceptCencora sources, warehouses, and distributes pharmaceuticals and related healthcare products to pharmacies, hospitals, health systems, clinics, and other care sites.
Specialty logistics
Cold-chain and specialty pharmaceutical logistics
1 conceptCencora's World Courier and related businesses provide specialty logistics for clinical trials, commercial therapies, temperature-controlled shipments, and complex treatments such as cell and gene therapies.
Technology waves
Strategic lenses
These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.
Bitcoin and Lightning as coordination rails
Proof-of-work economics, programmable payment flows, and anti-spam pricing make more digital systems capable of rewarding signal while resisting abuse.
- • Platforms that monetize gatekeeping could face pressure from protocol-native payment and reputation layers.
- • Micropayments can replace some ad-funded or subscription-heavy distribution models.
- • Open systems with credible anti-spam economics deserve a higher decentralizability score than legacy software assumptions suggest.
Paper trail
Visible evidence trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Cencora Investor Relations Overview
Cencora · investor relations
Company overview describing Cencora's role in healthcare supply-chain access and efficiency.
Reviewed 2026-06-02
Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results
Cencora · investor relations
Primary financial source for fiscal 2025 revenue, adjusted operating income, distribution-network investment, and management commentary.
Reviewed 2026-06-02
Cencora 2025 Form 10-K Annual Report Summary
StockTitan / SEC filing mirror · regulatory filing
Summarizes Cencora's 2025 Form 10-K business description, operating income movement, scale, and international exposure.
Reviewed 2026-06-02
World Courier and ICS Become First End-to-End Specialty Logistics Provider for Advanced Therapies
Cencora · product page
Describes Cencora specialty logistics capabilities for clinical trials, commercialization, cryogenic support, and advanced therapies.
Reviewed 2026-06-02
Cencora (COR) Stock Price, Statistics, and Market Cap
StockAnalysis · market data
Market-data source for market capitalization, P/E ratio, revenue TTM, EPS, and share data near the registry refresh date.
Reviewed 2026-06-02